GlassScriptPhysician profile
Ihsan U Khan
NPI 1578876991
$8,991.80
in general payments reported to CMS, 2019-2025
33 companies · $1,839 in 2025
The $1,839 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,806 · 2020: $217 · 2021: $643 · 2022: $1,911 · 2023: $1,656 · 2024: $921 · 2025: $1,839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,234 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,234.39 |
| Education | $181.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,109.73 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,155.47 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $879.50 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Electromed, INC. | $828.93 | 2019-2025 | Smartvest |
| Genzyme Corporation | $497.61 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $428.44 | 2019-2025 | Dupixent |
| Amgen INC. | $345.04 | 2022-2025 | Tezspire |
| Mallinckrodt Hospital Products INC. | $333.14 | 2022-2024 | Acthar |
| Grifols USA, LLC | $279.87 | 2019-2025 | Prolastin-C Liquid |
| Janssen Pharmaceuticals, INC | $258.06 | 2019-2022 | |
| Insmed, INC. | $216.61 | 2019-2025 | Arikayce |
| Verona Pharma, INC. | $206.54 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $205.21 | 2021-2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Actelion Pharmaceuticals US, INC. | $158.28 | 2024-2025 | Opsynvi, Opsumit, Uptravi |
| Genentech USA, INC. | $133.81 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $127.59 | 2021 | |
| Merck Sharp & Dohme LLC | $112.79 | 2025 | Winrevair |
| Novartis Pharmaceuticals Corporation | $110.84 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $82.42 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.70 | 2022-2023 | Glassia |
| Mylan Specialty L.P. | $72.27 | 2019-2022 | |
| Shire North American Group INC | $57.64 | 2019 | |
| Philips North America LLC | $45.44 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $45.27 | 2019 | |
| Inspire Medical Systems, INC. | $45.21 | 2025 | Inspire |
| Jazz Pharmaceuticals INC. | $42.67 | 2019 | |
| Circassia INC. | $41.10 | 2019 | |
| Csl Behring | $27.30 | 2020 | |
| Tactile Systems Technology INC | $21.24 | 2025 | Nimbl, Flexitouch Plus |
| Mallinckrodt Enterprises LLC | $17.51 | 2019 | |
| Itamar Medical INC | $17.28 | 2023 | Watchpatone |
| Pfizer INC. | $12.29 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ihsan Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.